All In Biotech

Drug Trial Radar · NCT07916883

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 18, 2026

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the feasibility of imaging atherosclerosis by 64Cu-NODAGA-CANF PET-MR in a pilot study of patients with asymptomatic carotid artery stenosis (ACAS). The main question it aims to answer is: Can 64Cu-NODAGA-CANF PET detect carotid atherosclerosis in patients with ACAS? Uptake of 64Cu-NODAGA-CANF as measured by PET-MR will also be correlated to anatomic features of plaque on MRI, outcomes for patients treated with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgery, and tissue measurements for patients undergoing CEA surgery. The ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients treated with OMT alone with respect to patient outcomes will be determined. Participants will * Receive a single intravenous (IV) administration of 64Cu-NODAGA-CANF followed by dynamic PET-MR imaging for up to 60 minutes and a second optional scan between 1-4 hours post-injection. * Undergo physical examinations, vital sign measurements, and blood and urine collection for clinical laboratory tests. * Undergo standard of care treatment with either OMT alone or OMT and CEA surgery. * Be evaluated with phone interviews 48-72 hours (2-3 days) after discharge and every 3 months (+/- 5 days) to assess for ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention.

Conditions

  • Carotid Atherosclerosis
  • Carotid Artery Stenosis Asymptomatic
  • Asymptomatic Carotid Artery Stenosis

Interventions

  • 64Cu-NODAGA-CANFDrug

    Patients will receive a single intravenous (IV) injection of 8-10 mCi of 64Cu-NODAGA-CANF for PET-MR imaging at the imaging visit.

  • Optimal Medical Therapy (OMT)Drug

    Patients will receive optimal medical therapy (OMT) as part of their standard of care treatment.

  • Carotid Endarterectomy (CEA) surgeryProcedure

    Patients will undergo carotid endarterectomy (CEA) surgery as part of their standard of care treatment. The plaque specimen will be collected during surgery for ex vivo tissue measurements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of 64Cu-NODAGA-CANF PET SUV (Standardized Uptake Value) between the atherosclerosis of the target diseased carotid artery and the non-diseased contralateral carotid artery or non-diseased vertebral arteryTime frame: Up to 4 hours post-injection of 64Cu-NODAGA-CANF

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.